Basilea Pharmaceutica AG | Ownership
Companies that own Basilea Pharmaceutica AG
Black Creek Investment Management, Inc.
537,206
4.51%
-308,097
0.48%
06/30/2017
Credit Suisse Asset Management (Schweiz) AG
386,587
3.25%
0
0.04%
12/31/2017
BlackRock Fund Advisors
303,773
2.56%
-55,492
0%
09/04/2018
The Vanguard Group, Inc.
275,870
2.31%
2,060
0%
07/31/2018
Zürcher Kantonalbank (Investment Management)
153,978
1.3%
4,257
0.03%
07/31/2018
UBS AG (Investment Management)
102,317
0.86%
8,605
0.01%
09/04/2018
Norges Bank Investment Management
90,381
0.76%
54,354
0%
12/31/2017
Deka Investment GmbH
63,538
0.54%
-77
0.01%
06/29/2018
CI Global Investments, Inc.
56,192
0.47%
-20,265
0.05%
06/30/2017
Franklin Templeton Investment Management Ltd.
48,500
0.41%
0
0.09%
06/30/2018
| Address |
Grenzacherstrasse 487
Basel Basel-Stadt (Basle Town) 4058
Switzerland
|
|
Employees
|
- |
| Website |
http://www.basilea.com |
| Updated |
07/08/2019 |
| Basilea Pharmaceutica AG is a biopharmaceutical company, with focus on bacterial infections, fungal infections and cancer. The company engages in the discovery, development, and commercialization of pharmaceutical products. Its products include Cresemba Isavuconazole, Zevtera/Mabelio Ceftobiprole, Toctino, and Microbiology Test. |
